Allspring Global Investments Holdings LLC Sells 54,376 Shares of RxSight, Inc. (NASDAQ:RXST)

Allspring Global Investments Holdings LLC trimmed its stake in RxSight, Inc. (NASDAQ:RXST) by 22.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 188,970 shares of the company’s stock after selling 54,376 shares during the period. Allspring Global Investments Holdings LLC’s holdings in RxSight were worth $7,619,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in RxSight by 4,739.2% in the first quarter. JPMorgan Chase & Co. now owns 565,506 shares of the company’s stock worth $9,433,000 after buying an additional 553,820 shares during the last quarter. BlackRock Inc. raised its stake in shares of RxSight by 30.6% in the second quarter. BlackRock Inc. now owns 1,629,928 shares of the company’s stock valued at $46,942,000 after acquiring an additional 382,119 shares during the period. Artisan Partners Limited Partnership raised its stake in shares of RxSight by 17.3% in the third quarter. Artisan Partners Limited Partnership now owns 2,437,765 shares of the company’s stock valued at $67,989,000 after acquiring an additional 359,295 shares during the period. Vanguard Group Inc. lifted its holdings in shares of RxSight by 89.1% in the 1st quarter. Vanguard Group Inc. now owns 638,813 shares of the company’s stock worth $7,908,000 after acquiring an additional 301,055 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in shares of RxSight by 64.4% during the 2nd quarter. Point72 Asset Management L.P. now owns 572,443 shares of the company’s stock worth $16,486,000 after purchasing an additional 224,275 shares during the period. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on RXST shares. Oppenheimer increased their price objective on shares of RxSight from $54.00 to $61.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of RxSight in a report on Thursday, April 11th. JPMorgan Chase & Co. raised their price target on RxSight from $40.00 to $62.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Finally, Stifel Nicolaus upped their price objective on RxSight from $54.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $49.63.

RxSight Stock Down 2.7 %

Shares of NASDAQ:RXST opened at $52.83 on Thursday. The firm’s 50 day simple moving average is $52.44 and its 200-day simple moving average is $40.54. RxSight, Inc. has a one year low of $17.00 and a one year high of $58.21.

RxSight (NASDAQ:RXST) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.10. The company had revenue of $28.58 million for the quarter, compared to analysts’ expectations of $28.60 million. RxSight had a negative return on equity of 31.16% and a negative net margin of 54.57%. As a group, equities analysts expect that RxSight, Inc. will post -0.94 earnings per share for the current year.

Insider Transactions at RxSight

In related news, CFO Shelley B. Thunen sold 20,000 shares of RxSight stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $49.90, for a total value of $998,000.00. Following the completion of the sale, the chief financial officer now directly owns 8,402 shares in the company, valued at $419,259.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director William J. Phd Link sold 28,250 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $49.67, for a total value of $1,403,177.50. Following the completion of the transaction, the director now owns 24,248 shares of the company’s stock, valued at $1,204,398.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Shelley B. Thunen sold 20,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $49.90, for a total value of $998,000.00. Following the sale, the chief financial officer now directly owns 8,402 shares in the company, valued at approximately $419,259.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 141,641 shares of company stock valued at $6,988,022. 21.13% of the stock is currently owned by corporate insiders.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.